Open AccessEffect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction
Author(s) -
Akshay S. Desai,
Scott D. Solomon,
Amil M. Shah,
Brian Claggett,
James C. Fang,
Joseph L. Izzo,
Kevin McCague,
Cheryl Abbas,
Ricardo Rocha,
Gary F. Mitchell,
for the EVALUATE-HF Investigators
Publication year - 2019
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2019.12843
Subject(s) - medicine , enalapril , sacubitril , ejection fraction , sacubitril, valsartan , cardiology , heart failure , valsartan , pulse wave velocity , blood pressure , angiotensin converting enzyme
Compared with enalapril, sacubitril-valsartan reduces cardiovascular mortality and heart failure hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). These benefits may be related to effects on hemodynamics and cardiac remodeling.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom